M. Milutinovic

1.5k total citations · 1 hit paper
12 papers, 1.0k citations indexed

About

M. Milutinovic is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, M. Milutinovic has authored 12 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Dermatology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in M. Milutinovic's work include Psoriasis: Treatment and Pathogenesis (11 papers), Dermatology and Skin Diseases (8 papers) and Autoimmune Bullous Skin Diseases (6 papers). M. Milutinovic is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (11 papers), Dermatology and Skin Diseases (8 papers) and Autoimmune Bullous Skin Diseases (6 papers). M. Milutinovic collaborates with scholars based in Switzerland, United States and China. M. Milutinovic's co-authors include R. You, Sophie Hugot, Diamant Thaçi, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Andrew Blauvelt, Michael Ziv and Andreas Pinter and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

M. Milutinovic

10 papers receiving 998 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by M. Milutinovic

Since Specialization

Citations

This map shows the geographic impact of M. Milutinovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Milutinovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Milutinovic more than expected).

Fields of papers citing papers by M. Milutinovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Milutinovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Milutinovic. The network helps show where M. Milutinovic may publish in the future.

Co-authorship network of co-authors of M. Milutinovic

This figure shows the co-authorship network connecting the top 25 collaborators of M. Milutinovic. A scholar is included among the top collaborators of M. Milutinovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Milutinovic. M. Milutinovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab 2024 ·Clinical and Experimental Dermatology ·Lewis E. Tomalin, Frank Kolbinger, Maria Suprun, Keith A. Wharton, Nicole Hartmann, Thomas Peters, (unknown), M. Milutinovic, James G. Krueger, Mayte Suárez‐Fariñas	1
2	Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies 2023 ·Clinical and Experimental Dermatology ·Mark Lebwohl, Lars Iversen, Liv Eidsmo, James G. Krueger, Mayte Suárez‐Fariñas, Lewis E. Tomalin, Frank Kolbinger, R. You, M. Milutinovic	10
3	Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events 2023 ·Journal of the European Academy of Dermatology and Venereology ·Robert Bissonnette, Lawrence F. Eichenfield, Eric L. Simpson, Diamant Thaçi, Kenji Kabashima, Jacob P. Thyssen, Emma Guttman‐Yassky, Fabio P. Nunes, Margaret Gamalo, Faiz Ahmad, Michael E. Kuligowski, Kang Sun, (unknown), (unknown), (unknown), M. Milutinovic, Achim Guettner, Jonathan I. Silverberg	3
4	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) 2018 ·Journal of the European Academy of Dermatology and Venereology ·Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, D. Toth, (unknown), (unknown), (unknown), Manmath Patekar, Pascal Charef, M. Milutinovic, C. Leonardi, Ulrich Mrowietz	144
5	Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment 2018 ·SKIN The Journal of Cutaneous Medicine ·(unknown), Kristian Reich, (unknown), Andrew Blauvelt, (unknown), (unknown), R. You, (unknown), M. Milutinovic, C.E.M. Griffiths	1
6	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial 2018 ·British Journal of Dermatology ·Kristian Reich, John Sullivan, Petr Arenberger, Ulrich Mrowietz, S. Jazayeri, Matthias Augustin, (unknown), P. Regnault, R. You, M. Milutinovic	76
7	Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial 2016 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, John Sullivan, Martijn B. A. van Doorn, А. А. Кубанов, R. You, (unknown), Sophie Hugot, M. Milutinovic	110
8	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study 2016 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, Stephen K. Tyring, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, R. You, M. Milutinovic, Diamant Thaçi	231
9	Supériorité du sécukinumab sur l’ustékinumab dans le psoriasis en plaques modéré à sévère de l’adulte : résultats de l’étude CLEAR à 1 an 2016 ·Annales de Dermatologie et de Vénéréologie ·J.‐P. Lacour, M. Ruer‐Mulard, A. Khemis, M. Beylot‐Barry, P. Celérier, Andrew Blauvelt, Kristian Reich, (unknown), Stephen K. Tyring, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, R. You, M. Milutinovic, (unknown), Lucie Martin, Diamant Thaçi	0
10	FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study 2016 ·Annals of the Rheumatic Diseases ·Kristian Reich, John Sullivan, Petr Arenberger, Ulrich Mrowietz, S. Jazayeri, Matthias Augustin, (unknown), P. Regnault, R. You, M. Milutinovic	12
11	Infections à Candida et infections récidivantes : analyse de 10 études cliniques de phases 2 et 3 de sécukinumab dans le psoriasis modéré à sévère 2016 ·Annales de Dermatologie et de Vénéréologie ·J.‐P. Lacour, A. Khemis, C. Paul, M. Ruer‐Mulard, P. Joly, Z. Reguiaï, Pierre‐André Bécherel, G. Guillet, M. Beylot‐Barry, C. Goujon, M.‐A. Richard, H. Bachelez, Claudia Conrad, Kristian Reich, Andrew Blauvelt, M. Milutinovic, Richard G. Langley, Lucie Martin, (unknown)	0
12	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial breakdown → 2015 ·Journal of the American Academy of Dermatology ·Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic	429

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact